Interferon beta-1a biosimilar - Biocad

Drug Profile

Interferon beta-1a biosimilar - Biocad

Alternative Names: BCD-033; interferon β1a - Biocad

Latest Information Update: 08 Mar 2017

Price : $50

At a glance

  • Originator Biocad
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Immunomodulators; Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Registered Multiple sclerosis

Most Recent Events

  • 03 Mar 2017 Registered for Multiple sclerosis in Russia (SC)
  • 31 Dec 2014 Biomarkers information updated
  • 01 Aug 2013 Biocad completes a phase I trial in Healthy volunteers in Russia (NCT01766024)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top